Adaptive Biotechnologies Corporation is a Research and Development Laboratories business in Seattle, WA.
| Business Name: | Adaptive Biotechnologies Corporation |
| Categorized In: | Research and Development Laboratories |
| Address: | 1551 Eastlake Avenue East # 200, Seattle, WA 98102 |
| Phone Number: | (206) 659-0067 |
| Contact Person: | Chad Robins |
| NAICS Code: | 541712 |
| SIC Code: | 8731 |
| Business Type: | B2B (Business to Business) |
| Founding Year: | 2009 |
| Employee #: | 1 to 4 |
| Location Type: | Single Location |
| Annual Revenue ($): | $500.000 to $999.999 |
| Share This Business: | |
| Similar Businesses: |
Acylin Therapeutics Inc - Seattle, WA 98102 Genewiz Inc - Seattle, WA 98102 Complex Chemicals Corp - Seattle, WA 98102 Arzeda - Seattle, WA 98102 Groove Biopharma - Seattle, WA 98102 Spi Surgical Inc - Seattle, WA 98102 Gilead Sciences Inc - Seattle, WA 98102 Tria Bioscience Corp - Seattle, WA 98102 Seredigm Corporation - Seattle, WA 98102 |
Adaptive Biotechnologies Corporation, a stable growing company under Research and Development Laboratories, is being run by Chad Robins. Since , their sales have been favorable and consistent at $500.000 to $999.999. Company location coordinates are: 47.633242,-122.325966.
It can be reached by dialing (206) 659-0067, and you could get in touch with their sales team in 1551 Eastlake Avenue East # 200, Seattle, Washington WA 98102. Visit their website at: to know more about the company’s history, products and services, as well as frequently asked questions and privacy policies.
Special deals are also offered from time to time. Their professional and honest business transactions fortifies both consumers and businesses in their B2B segments.
Their modest but solid single location houses 1 to 4 staff members. All are benefiting from the company’s generous programs and sound training solutions.
You can learn more by checking their classification codes: SIC – 8731 and NAIC – 541712. Call the hotline stated above for faster transaction and queries. Adaptive Biotechnologies Corporation would like to hear from you.